140 related articles for article (PubMed ID: 17094469)
1. MDM2 T309G polymorphism is associated with bladder cancer.
Onat OE; Tez M; Ozçelik T; Törüner GA
Anticancer Res; 2006; 26(5A):3473-5. PubMed ID: 17094469
[TBL] [Abstract][Full Text] [Related]
2. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
3. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
Hitzenbichler F; Stoehr CG; Rogenhofer M; Wieland WF; Ruemmele P; Hartmann A; Stoehr R
Pathobiology; 2014; 81(2):53-9. PubMed ID: 24217660
[TBL] [Abstract][Full Text] [Related]
4. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
5. The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener's granulomatosis.
Assmann G; Wieczorek S; Wibisono D; Roemer K; Arning L; Voswinkel J
Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S72-5. PubMed ID: 18799058
[TBL] [Abstract][Full Text] [Related]
6. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
[TBL] [Abstract][Full Text] [Related]
7. No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients.
Cho YG; Choi BJ; Song JH; Kim CJ; Cao Z; Nam SW; Lee JY; Park WS
Neoplasma; 2008; 55(3):256-60. PubMed ID: 18348658
[TBL] [Abstract][Full Text] [Related]
8. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population.
Wang M; Zhang Z; Zhu H; Fu G; Wang S; Wu D; Zhou J; Wei Q; Zhang Z
Clin Cancer Res; 2008 Jun; 14(11):3633-40. PubMed ID: 18519798
[TBL] [Abstract][Full Text] [Related]
9. Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish Population.
Yilmaz M; Tas A; Donmez G; Kacan T; Silig Y
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1059-1062. PubMed ID: 29699057
[TBL] [Abstract][Full Text] [Related]
10. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
[TBL] [Abstract][Full Text] [Related]
11. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
[TBL] [Abstract][Full Text] [Related]
12. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer.
Javid J; Mir R; Julka PK; Ray PC; Saxena A
Tumour Biol; 2015 Jul; 36(7):5425-32. PubMed ID: 25672611
[TBL] [Abstract][Full Text] [Related]
13. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer.
Yang M; Guo Y; Zhang X; Miao X; Tan W; Sun T; Zhao D; Yu D; Liu J; Lin D
Carcinogenesis; 2007 Sep; 28(9):1996-2001. PubMed ID: 17638920
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
Petenkaya A; Bozkurt B; Akilli-Ozturk O; Kaya HS; Gur-Dedeoglu B; Yulug IG
Anticancer Res; 2006; 26(6C):4975-7. PubMed ID: 17214373
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
16. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
17. Correlation between MDM2 T309G single nucleotide polymorphism and esophageal cancer susceptibility: An updated meta-analysis.
Yin L; Shen G; Zhu B
Thorac Cancer; 2020 Mar; 11(3):672-678. PubMed ID: 31970867
[TBL] [Abstract][Full Text] [Related]
18. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
19. The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma.
de Martino M; Taus C; Wessely IS; Lucca I; Hofbauer SL; Haitel A; Shariat SF; Klatte T
DNA Cell Biol; 2015 Feb; 34(2):107-12. PubMed ID: 25415135
[TBL] [Abstract][Full Text] [Related]
20. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]